NCT04779047

Comparative Therapeutic Efficacy and Safety of Different Antiviral and Anti Inflammatory Drugs in COVID-19 Patients.

Comparative Therapeutic Efficacy and Safety of Remdesivir Plus Lopinavir/ Ritonavir and Tocilizumab Versus Hydroxychloroquine Plus Ivermectin and Tocilizumab in COVID-19 Patients.

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 150 (estimated)
• Sponsor: October 6 University · Academic / Other
• Sex: All
• Age: 18 Years – 88 Years
• Healthy volunteers: Not accepted

Summary

Comparison outcomes of a large cohort of moderate and severe COVID-19 patients received different Antiviral and Anti Inflammatory Drugs.

Detailed description

Aim of the study 1. To assess the difference in patients' clinical status improvement between patients. 2. To detect time to improvement in oxygenation among both groups. 3. To detect duration of hospitalization and mortality rate in both groups. 4. To detect incidence and duration of mechanical ventilation in both treatment arms. 5. To monitor of adverse events of both drugs

Conditions

• Covid19
• Pneumonia

Interventions

Type	Name	Description
DRUG	Remdesivir	Remdesivir will be administrated intravenously (IV) at a dose of 200 mg at day 1 then 100 mg once daily for 5 days.
DRUG	Hydroxychloroquine	Hydroxychloroquine will be administrated at a dose of 400 mg twice daily at day 1 then 200 mg twice daily for 5 days.
DRUG	Tocilizumab	Tocilizumab 800 mg once.
DRUG	Lopinavir/ Ritonavir	Lopinavir / ritonavir at a dose of 400 /100 once daily for 5 days.
DRUG	Ivermectin	Ivermectin 36 mg at day 1,3 and 6.

Timeline

• Start date: 2020-10-01
• Primary completion: 2021-03-10
• Completion: 2021-04-05
• First posted: 2021-03-03
• Last updated: 2021-03-17

Locations

1 site across 1 country: Egypt